In conclusion, concentration of serum FABP4 may be not only a marker of metabolic syndrome that can be used even for ESRD patients but also a novel predictor of cardiovascular mortality in patients at high risk of atherosclerotic cardiovascular events. Here, FABP4 is linked to metabolic syndrome.